Scp 776
Alternative Names: Scp-776Latest Information Update: 30 Jul 2024
At a glance
- Originator Silver Creek Pharmaceuticals
- Class Heart failure therapies; Neuroprotectants; Recombinant fusion proteins; Urologics; Vascular disorder therapies
- Mechanism of Action Growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Stroke
- Phase I Brain injuries; Myocardial infarction
- Preclinical Acute lung injury; Heart failure; Kidney disorders
Most Recent Events
- 30 Jul 2024 Phase-I clinical trials in Brain injuries in USA (IV), prior to July 2024 (Silver creek pharmaceutical pipeline, July 2024)
- 30 Jul 2024 Phase-I clinical trials in Myocardial infarction in USA (IV), prior to July 2024 (Silver creek pharmaceutical pipeline, July 2024)
- 30 Jul 2024 Preclinical trials in Acute lung injury in USA (IV), prior to July 2024 (Silver creek pharmaceutical pipeline, July 2024)